市場調査レポート

商品コード

1630615

タンパク質分解標的キメラ分子の市場規模、シェア、成長分析：タイプ別、適応症別、技術別、用途別、エンドユーザー別、地域別 - 産業予測 2025～2032年

Proteolysis-targeting chimeric molecules Market Size, Share, Growth Analysis, By Type, By Indication, By Technology, By Application, By End-User, By Region - Industry Forecast 2025-2032

出版日: 2025年01月10日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 763,518円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 893,172円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,022,826円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

タンパク質分解標的キメラ分子（PROTACs）の世界市場規模は、2023年に1億2,546万米ドルと評価され、2024年の1億3,826万米ドルから2032年には3億70万米ドルに成長し、予測期間（2025～2032年）のCAGRは10.2％で成長する見通しです。

PROTAC（Proteolysis Targeting Chimeras）は画期的な治療アプローチであり、標準的な阻害ではなく、選択的かつ特異的な分解によって、これまで「治療不可能」であったタンパク質を標的とします。従来の結合制限を回避し、異なるタンパク質ドメインに結合するリガンドを利用することで、転写因子やキナーゼのような困難なタンパク質に効果的に関与します。この方法により、標的タンパク質をより包括的かつ持続的に阻害することができます。例えば、アンドロゲン受容体を標的とするものは前立腺がん細胞の増殖を抑制し、BCL-2を標的とするものは様々ながんでアポトーシスを誘導しました。有望な開発にもかかわらず、特に効果的な結合のためのリガンドの設計や、in vivoでの性能を高めるための薬物動態特性の最適化には課題が残っています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
市場の最近の動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 会社概要
- 製品ポートフォリオ分析
- セグメント別シェア分析
- 収益の前年比比較（2022～2024年）

主要企業プロファイル

Arvinas（USA）
C4 Therapeutics（USA）
Kymera Therapeutics（USA）
Nurix Therapeutics（USA）
Bristol Myers Squibb（USA）
Pfizer（USA）
Sanofi（France）
AstraZeneca（UK）
Roche（Switzerland）
Olema Pharmaceuticals（USA）
Radius Health（USA）
Loxo Oncology（USA）
Amphista Therapeutics（UK）
Monte Rosa Therapeutics（USA）
Dunad Therapeutics（UK）
Ranok Therapeutics（China）
Ubiquigent（UK）
Origami Therapeutics（USA）
Treeline Biosciences（USA）
Entact Bio（USA）

結論と推奨事項

Product Code: SQMIG35I2121

Global Proteolysis-targeting chimeric molecules (PROTACs) Market size was valued at USD 125.46 million in 2023 and is poised to grow from USD 138.26 million in 2024 to USD 300.7 million by 2032, growing at a CAGR of 10.2% during the forecast period (2025-2032).

PROTACs (Proteolysis Targeting Chimeras) represent a groundbreaking therapeutic approach, targeting previously "undruggable" proteins through selective and specific degradation rather than standard inhibition. They effectively engage with challenging proteins, such as transcription factors and kinases, by utilizing ligands that bind to distinct protein domains, circumventing traditional binding limitations. This method facilitates a more comprehensive and lasting inhibition of target proteins. Preclinical studies have demonstrated significant efficacy, showing PROTACs' potential in cancer therapies; for instance, one targeting the androgen receptor inhibited prostate cancer cell growth, while another targeting BCL-2 induced apoptosis in various cancers. Despite promising developments, challenges remain, particularly in designing ligands for effective binding and optimizing pharmacokinetic properties for enhanced in vivo performance.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Proteolysis-Targeting Chimeric Molecules (Protacs) market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Proteolysis-Targeting Chimeric Molecules (Protacs) Market Segmental Analysis

Global Proteolysis-targeting chimeric molecules (PROTACs) Market is segmented by Type, Indication, Technology, Application, End-User and region. Based on Type, the market is segmented into Small Molecule PROTACs, Peptide PROTACs and Protein-Based PROTACs. Based on Indication, the market is segmented into Cancer, Autoimmune Diseases and Neurodegenerative Disorders. Based on Technology, the market is segmented into Bifunctional and Monovalent. Based on Application, the market is segmented into Oncology, Neurodegenerative Diseases and Inflammatory Diseases. Based on End-User, the market is segmented into Pharmaceutical Companies, Academic and Research Institutions and Contract Research Organizations (Cros). Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Proteolysis-Targeting Chimeric Molecules (Protacs) Market

A key driving force behind the advancement of Proteolysis-Targeting Chimeric Molecules (PROTACs) is the growing demand for enhanced target specificity in drug development. Traditional small-molecule drugs typically exhibit a lack of specificity, often affecting multiple proteins and resulting in unintended side effects and potential toxicity. In contrast, PROTACs are meticulously engineered to hone in on a particular protein or even a specific domain within that protein. This heightened level of target specificity significantly mitigates the risk of off-target consequences, thereby improving the safety profile of these molecules and paving the way for innovative treatments for previously challenging diseases.

Restraints in the Global Proteolysis-Targeting Chimeric Molecules (Protacs) Market

One significant challenge facing the Proteolysis-Targeting Chimeric Molecules (PROTACs) market is the complexity of designing and synthesizing compounds that are both effective and safe. Achieving the right balance between the ligands' affinity for their specific targets and the potency of the E3 ligase recruiting ligand is crucial, yet difficult. Multiple factors, including steric hindrance, charge, and solubility, can affect ligand binding affinity. Furthermore, selecting the appropriate E3 ligase is critical, as certain E3 ligases may exhibit promiscuous activity, which can result in undesired off-target effects, complicating the development of reliable PROTAC therapeutics.

Market Trends of the Global Proteolysis-Targeting Chimeric Molecules (Protacs) Market

The Global Proteolysis-Targeting Chimeric Molecules (PROTACs) market is witnessing significant growth, driven by the escalating adoption of this innovative technology in drug discovery and development. By focusing on the degradation of disease-causing proteins rather than mere inhibition, PROTACs present a transformative approach that enhances therapeutic efficacy, particularly for diseases resistant to conventional treatments. As pharmaceutical companies and research institutions intensify their exploration of PROTACs, the market is experiencing a surge in research and development activities. This trend is poised to revolutionize treatment paradigms, attracting attention from investors and stakeholders, further propelling the PROTACs market towards expansive growth.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size by Type & CAGR (2025-2032)

Market Overview
Small Molecule PROTACs
Peptide PROTACs
Protein-Based PROTACs

Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size by Indication & CAGR (2025-2032)

Market Overview
Cancer
Autoimmune Diseases
Neurodegenerative Disorders

Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size by Technology & CAGR (2025-2032)

Market Overview
Bifunctional
Monovalent

Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size by Application & CAGR (2025-2032)

Market Overview
Oncology
Neurodegenerative Diseases
Inflammatory Diseases

Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size by End-User & CAGR (2025-2032)

Market Overview
Pharmaceutical Companies
Academic and Research Institutions
Contract Research Organizations (Cros)

Global Proteolysis-targeting chimeric molecules (PROTACs) Market Size & CAGR (2025-2032)

North America (Type, Indication, Technology, Application, End-User)
- US
- Canada
Europe (Type, Indication, Technology, Application, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Indication, Technology, Application, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Indication, Technology, Application, End-User)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Indication, Technology, Application, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Arvinas (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
C4 Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kymera Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nurix Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Olema Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Radius Health (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Loxo Oncology (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amphista Therapeutics (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Monte Rosa Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dunad Therapeutics (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ranok Therapeutics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ubiquigent (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Origami Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Treeline Biosciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Entact Bio (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

タンパク質分解標的キメラ分子の市場規模、シェア、成長分析：タイプ別、適応症別、技術別、用途別、エンドユーザー別、地域別 - 産業予測 2025～2032年

Proteolysis-targeting chimeric molecules Market Size, Share, Growth Analysis, By Type, By Indication, By Technology, By Application, By End-User, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

世界のタンパク質分解標的キメラ分子（PROTAC）市場規模：タイプ別

世界のタンパク質分解標的キメラ分子（PROTAC）市場規模：適応症別

世界のタンパク質分解標的キメラ分子（PROTAC）市場規模：技術別

世界のタンパク質分解標的キメラ分子（PROTAC）市場規模：用途別

世界のタンパク質分解標的キメラ分子（PROTAC）市場規模：エンドユーザー別

世界のタンパク質分解標的キメラ分子（PROTAC）市場規模